|
業務類別
|
Biotechnology |
|
業務概覽
|
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
| 公司地址
| Winzerlaer Strasse 2, Jena, DEU, 07745 |
| 電話號碼
| +49 3641508180 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.inflarx.de |
| 員工數量
| 65 |
| Professor Niels Riedemann |
Executive Director and Chief Executive Officer |
-- |
21/03/2024 |
| Professor Dr. Renfeng Guo, M.D. |
Executive Director and Chief Scientific Officer |
-- |
21/03/2024 |
| Dr. Thomas Taapken |
Chief Financial Officer |
-- |
21/03/2024 |
| Dr. Camilla Chong |
Chief Medical Officer |
-- |
21/03/2024 |
| Ms. Derval O’Carroll |
Senior Vice President and Global Head, Regulatory Affairs and Compliance |
-- |
21/03/2024 |
|
|
| Mr. Richard H. Brudnick |
Independent Director |
21/03/2024 |
| Mr. Nicolas Fulpius |
Non-Executive Chairman of the Board |
21/03/2024 |
| Professor Niels Riedemann |
Executive Director and Chief Executive Officer |
21/03/2024 |
| Mr. Mark Kubler |
Independent Director |
21/03/2024 |
| Professor Dr. Renfeng Guo, M.D. |
Executive Director and Chief Scientific Officer |
21/03/2024 |
| Mr. Anthony Gibney |
Independent Director |
21/03/2024 |
| Ms. Hege Hellstrom |
Director |
21/03/2024 |
|
|
|
|
